Figure 2
Figure 2. In vitro half-life studies in HB plasma. Factor Xa (20 nM wt-FXa [●]; zymogen-like 1: FXa-V17M [□]; zymogen-like 2: FXa-I16L [▪], FXa-I16M [▼], FXa-V17T [▿]; zymogen-like 3: FXa-V17S [△] and 60 nM FXa-I16T [▲]) were incubated in (A) human or (B) mouse HB plasma at the indicated time points, and residual activity was assessed by clotting assay. The solid lines were drawn after analysis of data sets to an exponential decay function with the following fitted parameters for half-life. The fitted parameters for the (A) human proteins can be found in Table 2 and those for (B) mouse proteins are as follows: FXa-I16T ∼60 minutes, FXa-V17S ∼17 minutes, FXa-I16M ∼9 minutes, FXa-I16L ∼5 minutes7, FXa-V17M ∼1.2 minutes, and wt-FXa 0.15 minutes. The data are representative of 3 similar experiments.

In vitro half-life studies in HB plasma. Factor Xa (20 nM wt-FXa [●]; zymogen-like 1: FXa-V17M [□]; zymogen-like 2: FXa-I16L [▪], FXa-I16M [▼], FXa-V17T [▿]; zymogen-like 3: FXa-V17S [△] and 60 nM FXa-I16T [▲]) were incubated in (A) human or (B) mouse HB plasma at the indicated time points, and residual activity was assessed by clotting assay. The solid lines were drawn after analysis of data sets to an exponential decay function with the following fitted parameters for half-life. The fitted parameters for the (A) human proteins can be found in Table 2 and those for (B) mouse proteins are as follows: FXa-I16T ∼60 minutes, FXa-V17S ∼17 minutes, FXa-I16M ∼9 minutes, FXa-I16L ∼5 minutes7 , FXa-V17M ∼1.2 minutes, and wt-FXa 0.15 minutes. The data are representative of 3 similar experiments.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal